SEC Form 4 · accession 0001567619-18-007640
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony G. Quinn
Officer — President & CEO · Director
Period of report
Dec 7, 2018
Accepted (ET)
Dec 10, 2018 · 5:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 15, 2018 | P | 2,000 | $6.02 | A | 94,793 | D | |
| Common StockF1 | Aug 15, 2018 | P | 994 | $9.13 | A | 95,787 | D | |
| Common Stock | Dec 7, 2018 | M | 150,000 | $4.11 | A | 245,787 | D | |
| Common Stock | Dec 7, 2018 | M | 3,306 | $5.46 | A | 249,093 | D | |
| Common Stock | Dec 7, 2018 | M | 18,584 | $6.31 | A | 267,677 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F2 | $4.11 | Dec 7, 2018 | M | 150,000 | D | — | Aug 30, 2027 | Common Stock | 150,000 | 0 | D |
| Director Stock Option (right to buy)F3 | $5.46 | Dec 7, 2018 | M | 3,306 | D | — | Mar 17, 2026 | Common Stock | 3,306 | 1,985 | D |
| Director Stock Option (right to buy)F4 | $6.31 | Dec 7, 2018 | M | 18,584 | D | — | Feb 19, 2028 | Common Stock | 18,584 | 144,950 | D |
Explanation of responses
- F1These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- F2The stock option vested and became exercisable as to 100% of the shares subject to the option on July 18, 2018, subject to the continuing service of the Reporting Person on the vesting date.
- F3The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
- F4The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.